Below are frequently asked questions regarding Corgenix Medical Corporation. If you have any additional questions or comments please feel free to contact us. 

Question:    When was Corgenix Medical Corporation founded and what is its line of business?

Answer:      Corgenix Medical Corporation is a medical products company with one main subsidiary; Corgenix, Inc.. Corgenix Inc.’s principal focus has been the discovery and development of novel diagnostic markers for the detection and management of important vascular and immunological disorders.  Until May 22, 1998, this business was conducted by and under the name of REAADS Medical Products, Inc.  REAADS Medical Products was a private company, founded in 1990. On May 22, 1998, REAADS became a subsidiary of Corgenix Medical Corporation, and its name was changed to Corgenix, Inc.. 


Question:     How many products are currently manufactured and marketed by Corgenix,Inc.?

Answer:   Currently, Corgenix, Inc. has developed over 43 products used in clinical laboratories for the diagnosis and/or monitoring of four areas of healthcare—autoimmune disorders, vascular diseases, bone and joint diseases and liver diseases. Presently, Corgenix, Inc. markets over 50 products worldwide.

Question:     Where is the research and manufacturing of the current diagnostic products done?

Answer:        All research and manufacturing of products is done at the corporate headquarters located in Denver (Broomfield) Colorado.

Question:      How large of a company is Corgenix Medical Corporation?

Answer:       Corgenix Medical Corporation currently employs approximately 36 employees in its Denver location,  as well as sales representatives nationwide. 

Question:      What stock exchange is Corgenix Medical Corporation traded on?

Answer:        Corgenix is traded on the NASD OTC Bulletin Board under the symbol CONX.

Question:      How many shares of common stock are authorized and freely tradable?

Answer:         As of December 1, 2010 the total number of common shares issued and outstanding is 40,918,853. 

Question:      What percentage of stock is currently beneficially owned by directors and officers of the company?

Answer:        Directors and/or officers of the company beneficially own approximately 14.0 percent of the stock.